Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081395 | 1.00 | MAPT (0.73) | MAPTOPRM1FUCA1OPRD1OPRK1 | |
| SCHEMBL29081398 | 1.00 | MAPT (0.73) | MAPTOPRM1FUCA1OPRD1OPRK1 | |
| SCHEMBL31145214 | 1.00 | MAPT (0.73) | MAPTOPRM1FUCA1OPRD1OPRK1 | |
| SCHEMBL24365249 | 0.86 | MAPT (0.56) | MAPTOPRM1OPRD1OPRK1TP53 | |
| SCHEMBL23564629 | 0.84 | MAPT (1.00) | MAPTFUCA1GBA1 | |
| SCHEMBL23527228 | 0.84 | MAPT (1.00) | MAPTFUCA1GBA1 | |
| SCHEMBL23564402 | 0.84 | MAPT (1.00) | MAPTFUCA1GBA1 | |
| SCHEMBL23564320 | 0.84 | MAPT (1.00) | MAPTFUCA1GBA1 | |
| SCHEMBL30471064 | 0.82 | MAPT (0.52) | MAPTOPRM1OPRD1OPRK1TP53 | |
| SCHEMBL26994370 | 0.80 | MAPT (0.50) | MAPTOPRM1FUCA1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | MAPT 2749/4885OPRM1 286/4885FUCA1 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.